KRYS - Krystal Biotech, Inc.

263.8
4.990   1.892%

Share volume: 223,201
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$258.81
4.99
0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
11%
Profitability 15%
Dept financing 3%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.30%
1 Month
-1.98%
3 Months
18.85%
6 Months
76.16%
1 Year
50.55%
2 Year
64.93%
Key data
Stock price
$263.80
P/E Ratio 
34.90
DAY RANGE
$253.70 - $268.26
EPS 
$7.08
52 WEEK RANGE
$122.80 - $298.30
52 WEEK CHANGE
$46.51
MARKET CAP 
7.149 B
YIELD 
N/A
SHARES OUTSTANDING 
29.232 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-04-2025
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$258,013
AVERAGE 30 VOLUME 
$311,507
Company detail
CEO: Krish S. Krishnan
Region: US
Website: krystalbio.com
Employees: 210
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.

Recent news